{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:48:57Z","timestamp":1780598937309,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.cardfail.2022.06.005","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T03:04:05Z","timestamp":1657767845000},"page":"1509-1518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6754-3670","authenticated-orcid":false,"given":"TREJEEVE","family":"Martyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOSHUA","family":"SAEF","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MUZNA","family":"HUSSAIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LAUREN","family":"IVES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALAN","family":"KIANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JERRY D.","family":"ESTEP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PATRICK","family":"COLLIER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RANDALL C.","family":"STARLING","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PAUL C.","family":"CREMER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.H. WILSON","family":"TANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MAZEN","family":"HANNA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5642-2112","authenticated-orcid":false,"given":"WAEL A.","family":"JABER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2022.06.005_bib0001","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0002","doi-asserted-by":"crossref","unstructured":"E. Gonzalez-Lopez, M. Gallego-Delgado, G. Guzzo-Merello, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction Eur Heart J 2015; 36: 2585\u201394","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0003","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","article-title":"Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week","volume":"75","author":"Hanna","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0004","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0006","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0007","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jcmg.2020.08.027","article-title":"Diagnosing transthyretin cardiac amyloidosis by technetium 99m pyrophosphate: a test in evolution","volume":"14","author":"Poterucha","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0008","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"16","key":"10.1016\/j.cardfail.2022.06.005_bib0009","first-page":"426","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"709","key":"10.1016\/j.cardfail.2022.06.005_bib0011","first-page":"416","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0012","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0013","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Casta\u00f1o","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0014","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0015","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0016","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0017","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI Expert Consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0018","first-page":"854","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization","volume":"25","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0019","doi-asserted-by":"crossref","unstructured":"V Singh, R Falk, MF Di Carli, M Kijewski, C Rapezzi, S Dorbala. State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nucl Cardiol 2019;26:158\u201373.","DOI":"10.1007\/s12350-018-01552-4"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0020","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.010249","article-title":"Efficient 1-hour technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis","volume":"13","author":"Masri","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0021","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/jamacardio.2016.5885","article-title":"Prognosis using planar imaging in cardiac amyloidosis","volume":"2","author":"Sperry","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0022","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s12350-015-0261-x","article-title":"Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis","volume":"23","author":"Casta\u00f1o","year":"2016","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0023","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jcmg.2016.06.003","article-title":"Can 99mTc-pyrophosphate aid in early detection of cardiac involvement in asymptomatic variant TTR amyloidosis?","volume":"10","author":"Haq","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0024","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ejhf.2028","article-title":"Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis","volume":"23","author":"B\u00e9zard","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0025","first-page":"713","article-title":"Initial experience prescribing commercial tafamidis, the most expensive cardiac medication in history","volume":"10","author":"Masri","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2022.06.005_bib0026","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916422005814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916422005814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:48:07Z","timestamp":1761029287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916422005814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1071916422005814"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2022.06.005","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2022.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2022.08.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}